Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Cipla shares end almost 3% higher on regulator nod to manufacture remdesivir

India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said.

June 23, 2020 / 12:39 PM IST
X

Cipla share price jumped almost 3 percent on June 22 after the country's drug regulator on June 20 gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir.

The stock ended at Rs 655.80, up Rs 18.70, or 2.94 percent. It has touched a 52-week high of Rs 696. It traded with volumes of 1,313,721 shares, compared to its five day average of 177,955 shares, an increase of 638.23 percent.

India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), considering the emergency and unmet need for medicines in light of the coronavirus outbreak, granted domestic firm Glenmark Pharmaceuticals the permission to manufacture and market favipiravir for "restricted emergency use" in mild to moderate cases.

The Union health ministry, in its 'Clinical Management Protocols for COVID-19', recommended the use of the remdesivir on patients in moderate stage of the disease that is, those on oxygen. The drug has been included as an "investigational therapy" only for restricted emergency use purposes.

Cipla and Hetero Labs have already entered into non-exclusive licensing agreements with US pharma giant Gilead Sciences, which is the patent holder of the drug remdesivir.

Sandip Das
first published: Jun 22, 2020 09:42 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347